2012
DOI: 10.1161/res.0b013e3182582523
|View full text |Cite|
|
Sign up to set email alerts
|

Animal Models of Heart Failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
223
0
1

Year Published

2013
2013
2021
2021

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 385 publications
(239 citation statements)
references
References 250 publications
6
223
0
1
Order By: Relevance
“…Before performing reverse‐phase protein microarray, therefore, we used the rat brain as a Ca v 2.2‐α–positive sample and the gastrocnemius muscle as a Ca v 2.2‐α–negative sample to evaluate target specificity of Ca v 2.2‐α antibody (Figure 2). Additionally, we do realize a possible limitation of small animals for extrapolating the findings obtained in this study to humans, although the rat has contributed markedly to assessment of the pathophysiology and treatment of CHF and to the advancement of clinical care 53, 54, 55. Large animals could be an appropriate alternative for translational experiments.…”
Section: Discussionmentioning
confidence: 94%
“…Before performing reverse‐phase protein microarray, therefore, we used the rat brain as a Ca v 2.2‐α–positive sample and the gastrocnemius muscle as a Ca v 2.2‐α–negative sample to evaluate target specificity of Ca v 2.2‐α antibody (Figure 2). Additionally, we do realize a possible limitation of small animals for extrapolating the findings obtained in this study to humans, although the rat has contributed markedly to assessment of the pathophysiology and treatment of CHF and to the advancement of clinical care 53, 54, 55. Large animals could be an appropriate alternative for translational experiments.…”
Section: Discussionmentioning
confidence: 94%
“…2005; Monnet and Chachques 2005; Canty and Suzuki 2012; Houser et al. 2012; Isorni et al. 2015; Mohammed et al.…”
Section: Introductionmentioning
confidence: 99%
“…Initially, cardiac remodeling is a beneficial compensatory process, which reduces cardiac wall stress and increases cardiac output, but remodeling ultimately results in the inability of the heart to meet hemodynamic demands. Despite a number of important therapeutic advances in the treatment of symptomatic HF, the prevalence, mortality and cost associated with HF continue to increase (4). Therefore, the development of novel therapeutic strategies to attenuate cardiac remodeling and prevent heart failure is an urgent goal for the biomedical community.…”
Section: Introductionmentioning
confidence: 99%